Idarucizumab reversal of dabigatran in sheep
Reference paper ↗A PK/PD model coupling dabigatran central, peripheral, and effect-site disposition to idarucizumab-associated reversal of the anticoagulation response in sheep.
- Therapeutic
- Dabigatran challenge and idarucizumab reversal, Idarucizumab
- Modality
- Antibody fragment
- Target
- Thrombin, Dabigatran
- Disease
- Preclinical reversal of dabigatran anticoagulation
- Model type
- PKPD
Complete model workspace
Checking workspace access…
- Parameters
- 14
- States
- 6
- Equations
- 6
- Derived outputs
- 8
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
4 mg/kg dabigatran sheep PK-PD
How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing? Explore this intervention regimen through Dabigatran effect-site concentration, Idarucizumab reversal effect, Central dabigatran amount, Circuit dabigatran amount, Cumulative dabigatran exposure.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–1,440 minute; step 5
| Input | Default | Available range |
|---|---|---|
| Standardized systemic clearance | 0.0453 L/min | 0.02265–0.06795 L/min |
| Standardized central distribution volume | 2.94 L | 1.47–4.41 L |
| Standardized intercompartmental clearance | 0.268 L/min | 0.134–0.402 L/min |
| Effect-compartment half-life | 1.04 min | 0.52–1.56 min |
| Idarucizumab binding rate | 0.0218 1/min | 0.0109–0.0327 1/min |
Expected readouts
Effect-site concentration (mg/L) · Idarucizumab reversal effect (dimensionless) · Central-compartment drug amount (mg) · Circuit dabigatran amount (mg) · Exposure (AUC) (mg*min/L)
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 14 declared model parameters.
More key parameters (1)
How the model represents the biology
A PK/PD model coupling dabigatran central, peripheral, and effect-site disposition to idarucizumab-associated reversal of the anticoagulation response in sheep.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: An idarucizumab dose or concentration, dabigatran binding or neutralization, and a coupled reversal response are not represented; the idarucizumab state is an independent initialized signal.
Modeled relationships (5)
- Dabigatran input → Central dabigatran: drug input (flow)
- Central dabigatran ↔ Peripheral dabigatran: distribution (reversible exchange)
- Central dabigatran → Dabigatran clearance: systemic CL (loss)
- Central dabigatran → Effect-site concentration: equilibration (modulation)
- Idarucizumab signal → Signal decay: first-order (loss)
Modeled relationships: Dabigatran input to Central dabigatran: drug input (flow); Central dabigatran reversibly exchanges with Peripheral dabigatran: distribution (reversible exchange); Central dabigatran to Dabigatran clearance: systemic CL (loss); Central dabigatran to Effect-site concentration: equilibration (modulation); Idarucizumab signal to Signal decay: first-order (loss).
Primary readouts: Dabigatran effect-site concentration; Idarucizumab-effect signal; Central dabigatran; Cumulative exposure.
Related models
Research use only — not for patient-specific prediction or dosing advice.
